Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer

Baigent, Amy; Lashen, Hany

doi:10.1016/j.fertnstert.2011.03.070

Cited by 6 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovarian cysts may result from functional cysts, primary ovarian tumor including ovarian cancer, or metastasis of breast cancer. It is reported that some patients with tamoxifen-induced cysts need surgical intervention because of vascular torsion [ 13 ], cystic necrosis without vascular torsion [ 14 ], or ovarian hyperstimulation syndrome [ 15 ], or to rule out the possibility of malignant tumor. Elevated levels of serum estrogen may cause thrombotic events, endometrial hyperplasia, and uterine cancer [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer

Kojima

Yamasaki

Koh

et al. 2018

Case Reports in Obstetrics and Gynecology

View full text Add to dashboard Cite

Tamoxifen treatment for breast cancer may induce ovarian cysts and supraphysiological levels of serum estrogen. We report successful management with luteinizing hormone-releasing hormone (LHRH) agonist of ovarian hyperstimulation induced by tamoxifen. A 49-year-old woman was operated on for invasive ductal carcinoma of the right breast. She received breast irradiation and adjuvant tamoxifen therapy. After 2 years, she had a cystic ovarian mass, and her serum concentration of estradiol was 1280 pg/mL. She was treated with an injection of 11.25 mg leuprolide acetate, a long-acting LHRH agonist, without abandoning tamoxifen therapy. The levels of estradiol decreased to <10 pg/mL and the cystic mass disappeared 2 months later. Three-month depot treatment with LHRH agonists can be useful for patients receiving tamoxifen for breast cancer who have ovarian cysts and supraphysiological levels of estrogen.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer

Kojima

Yamasaki

Koh

et al. 2018

Case Reports in Obstetrics and Gynecology

View full text Add to dashboard Cite

show abstract

“…Occasionally, OHSS may occur following clomiphene ovulation induction, during the agonist phase of GnRH agonist monotherapy [ 4 , 5 ] or following monotherapy with an anti-estrogen such as tamoxifen [ 6 ]. Rarely a spontaneous pregnancy may cause OHSS [ 7 ].…”

Section: Pathophysiologymentioning

confidence: 99%

Ovarian Hyperstimulation Syndrome (OHSS)

Barbieri

2013

Endocrine Emergencies

View full text Add to dashboard Cite

Précis1. Clinical Setting: abdominal bloating and distention, intravascular volume depletion, ascites, hemoconcentration, and oliguria following a fertility intervention involving the administration of exogenous FSH. of a GnRH agonist to stimulate endogenous LH secretion to trigger ovarian follicle luteinization in order to reduce ovarian production of VEGF. Cessation of FSH stimulation (coasting), in order to reduce the ovarian production of VEGF. Freezing all embryos and cancelling embryo transfer to avoid a late case of OHSS caused by pregnancy. Administration of a dopamine agonist such as cabergoline to reduce ovarian production of VEGF.

show abstract

Ovarian Hyperstimulation Syndrome (OHSS)

Barbieri¹

2021

Contemporary Endocrinology

View full text Add to dashboard Cite

Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer

Cited by 6 publications

References 28 publications

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer

Ovarian Hyperstimulation Syndrome (OHSS)

Ovarian Hyperstimulation Syndrome (OHSS)

Contact Info

Product

Resources

About